Genmab — Juli 2016
-
God timing af FDA lige før vores Q&A.

-
Jeg tror ikke, at der går lang tid før ansøgningen er inde.
-
Er den mest præcise indikation vi har ikke Q3? Mener det er det Jan tidligere har udtalt. Jeg forventer den kommer rimeligt hurtigt, da J&J kender stof og proces i detaljer. Det eneste der kan forlænge processen er hvis der er en reel drøftelse med FDA om udvidelse af indikationen (måske jeg drømmer)
-
Drøm bare videre Bud.

-
Vi er 1/3 inde i Q3.

-
Jeg kommenterer på Børsen Play kl. 11,15.
-
I morgen.

-
Novod positiv og ser mulig godkendelse allerede i 2016. Tilføjer: "
Looking beyond multiple myeloma, we would not rule out the possibility of BTDs in other indications like in lymphomas, leukaemia and solid tumours, but that will of course depend on the early data when the first of that is reported later in 2016 and into 2017"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind